Literature DB >> 4881068

The effects of drugs on Onchocerca volvulus. 3. Trials of suramin at different dosages and a comparison of the brands Antrypol, Moranyl and Naganol.

B O Duke.   

Abstract

Suramin and Mel W are the only two drugs at present known to be effective against the adult worms of Onchocerca volvulus, but in view of the unpredictable occurrence of fatal arsenical encephalopathy in a small proportion of patients receiving Mel W, suramin remains the preferred macrofilaricide in the treatment of onchocerciasis. It is therefore important to determine the suramin dosage schedules that will produce parasitological cures with minimal concomitant risks of toxic reactions. The criteria by which cures should be judged must also be appreciated.Courses of different duration and employing doses of 1.0 g, 0.5 g and 0.25 g suramin have been investigated for their action on adult worms and microfilariae, for the toxic reactions which they produce on the kidney, and for the level of suramin reached in the serum during treatment. A course of 5 or 6 weekly doses of 1.0 g has been shown to be the optimum for adults.It is sometimes stated without good foundation that different brands of suramin differ in their purity and chemical composition, thus producing inconsistent effects on the parasites and grave risks of toxic manifestations. The three main brands in current use in Africa (Antrypol, Moranyl and Naganol) have therefore been compared in a group of patients, using the same optimum dosage schedule for each preparation and recording the action of the various brands on the parasites, as well as their comparative toxicities and the serum suramin levels achieved. No significant differences between the brands were recorded.

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 4881068      PMCID: PMC2554546     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  6 in total

1.  The reappearance, rate of increase and distribution of the microfilariae of Onchocerca volvulus following treatment with diethylcarbamazine.

Authors:  B O DUKE
Journal:  Trans R Soc Trop Med Hyg       Date:  1957-01       Impact factor: 2.184

2.  Experimental therapy of onchocerciasis with suramin and hetrazan; results of a three-year study.

Authors:  T A BURCH; L L ASHBURN
Journal:  Am J Trop Med Hyg       Date:  1951-09       Impact factor: 2.345

3.  Studies on Bayer 205 (Germanin) and Antrypol: Further observations on the method of determination and on the retention of this drug in the animal body.

Authors:  J C Boursnell; W G Dangerfield; A Wormall
Journal:  Biochem J       Date:  1939-01       Impact factor: 3.857

4.  Studies on Bayer 205 (Germanin) and Antrypol: The determination of small amounts of Bayer 205 (and Antrypol). II. The persistence of Bayer 205 in the blood stream after injection into animals.

Authors:  W G Dangerfield; W E Gaunt; A Wormall
Journal:  Biochem J       Date:  1938-01       Impact factor: 3.857

5.  The estimation of suramin in plasma.

Authors:  J C Gage; F L Rose; M Scott
Journal:  Biochem J       Date:  1948       Impact factor: 3.857

6.  Onchocerca-Simulium complexes. I. Transmission of forest and Sudan-savanna strains of Onchocerca volvulus, from Cameroon, by Simulium damnosum from various West African bioclimatic zones.

Authors:  B O Duke; D J Lewis; P J Moore
Journal:  Ann Trop Med Parasitol       Date:  1966-09
  6 in total
  7 in total

1.  The risk of optic atrophy following suramin treatment of ocular onchocerciasis.

Authors:  B Thylefors; A Rolland
Journal:  Bull World Health Organ       Date:  1979       Impact factor: 9.408

2.  Chemotherapeutic studies on Litomosoides carinii infection of Mastomys natalensis. 3. The activity of drugs against adult parasites.

Authors:  G Lämmler; H Herzog; H R Schütze
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

3.  [Treatment of onchocerciasis in hyperendemic communities in West Africa with small, gradually increasing doses of suramin. 1. Parasitological results and ophthalmological surveillance in a region where transmission has not been interrupted].

Authors:  A Rougemont; B Thylefors; M Ducam; A Prost; P Ranque; J Delmont
Journal:  Bull World Health Organ       Date:  1980       Impact factor: 9.408

4.  Further studies on the treatment of ocular onchocerciasis with diethylcarbamazine and suramin.

Authors:  J Anderson; H Fuglsang
Journal:  Br J Ophthalmol       Date:  1978-07       Impact factor: 4.638

5.  Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate.

Authors:  A C Bird; H el-Sheikh; J Anderson; H Fuglsang
Journal:  Br J Ophthalmol       Date:  1980-03       Impact factor: 4.638

Review 6.  Repurposing clinical drugs is a promising strategy to discover drugs against Zika virus infection.

Authors:  Weibao Song; Hongjuan Zhang; Yu Zhang; Rui Li; Yanxing Han; Yuan Lin; Jiandong Jiang
Journal:  Front Med       Date:  2020-12-28       Impact factor: 4.592

Review 7.  Onchocerciasis drug development: from preclinical models to humans.

Authors:  Adela Ngwewondo; Ivan Scandale; Sabine Specht
Journal:  Parasitol Res       Date:  2021-10-13       Impact factor: 2.289

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.